TrialJournal for immunotherapy of cancer2020

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.

Jieqiong Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.